Debra Pratt1, Talia Burneikis2, Chao Tu2, Stephen Grobmyer3. 1. Breast Surgery, Cleveland Clinic Ohio, 18200 Lorraine Ave, Cleveland, OH, 44111, USA. deprat@ccf.org. 2. Cleveland Clinic Ohio, Cleveland, OH, USA. 3. Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
Abstract
BACKGROUND: Breast cancer treatment delays are common. This study was designed to examine the association between the time interval from time of diagnosis to completion of all acute breast cancer treatment modalities (surgery, chemotherapy, and radiation therapy) and survival. METHODS: A retrospective analysis was performed utilizing data from the National Cancer Database (NCDB) to determine an association between the duration of time from diagnosis to completing all acute breast cancer treatment (surgery, chemotherapy, and radiation therapy) and survival. Secondary survival analysis evaluated whether delay in treatment completion varied by differences in tumor receptor status. RESULTS: We analyzed 2010 NCDB data of stage I-III breast cancer patients. A subset of 28,284 patients received all three modalities (surgery, chemotherapy, and radiation) as their acute treatment. Median follow-up was 5.8 years. Cox proportional hazards model identified a cut-off showing the risk of delaying completion of all treatment beyond 38 weeks was associated with a decrease in overall survival (hazard ratio [HR] 1.21). This decrease in survival was significant regardless of the major tumor receptor status: triple-negative (HR 1.188, 95% confidence interval [CI] 1.06-1.34), estrogen receptor (ER)+/progesterone receptor (PR)+/human epidermal growth factor receptor 2 (HER2)- (HR 1.22, 95% CI 1.09-1.36), ER-/PR-/HER2+ (HR 1.29, 95% CI 1.004-1.67), and ER+/PR+/HER2+ (HR 1.32, 95% CI 1.01-1.72). CONCLUSION: Efforts to improve the efficiency of multimodality breast cancer treatment and reduce treatment delays should be a priority to optimize breast cancer patient outcomes.
BACKGROUND:Breast cancer treatment delays are common. This study was designed to examine the association between the time interval from time of diagnosis to completion of all acute breast cancer treatment modalities (surgery, chemotherapy, and radiation therapy) and survival. METHODS: A retrospective analysis was performed utilizing data from the National Cancer Database (NCDB) to determine an association between the duration of time from diagnosis to completing all acute breast cancer treatment (surgery, chemotherapy, and radiation therapy) and survival. Secondary survival analysis evaluated whether delay in treatment completion varied by differences in tumor receptor status. RESULTS: We analyzed 2010 NCDB data of stage I-III breast cancerpatients. A subset of 28,284 patients received all three modalities (surgery, chemotherapy, and radiation) as their acute treatment. Median follow-up was 5.8 years. Cox proportional hazards model identified a cut-off showing the risk of delaying completion of all treatment beyond 38 weeks was associated with a decrease in overall survival (hazard ratio [HR] 1.21). This decrease in survival was significant regardless of the major tumor receptor status: triple-negative (HR 1.188, 95% confidence interval [CI] 1.06-1.34), estrogen receptor (ER)+/progesterone receptor (PR)+/humanepidermal growth factor receptor 2 (HER2)- (HR 1.22, 95% CI 1.09-1.36), ER-/PR-/HER2+ (HR 1.29, 95% CI 1.004-1.67), and ER+/PR+/HER2+ (HR 1.32, 95% CI 1.01-1.72). CONCLUSION: Efforts to improve the efficiency of multimodality breast cancer treatment and reduce treatment delays should be a priority to optimize breast cancerpatient outcomes.
Authors: Michael J Raphael; James J Biagi; Weidong Kong; Mihaela Mates; Christopher M Booth; William J Mackillop Journal: Breast Cancer Res Treat Date: 2016-09-08 Impact factor: 4.872
Authors: Amanda R Kupstas; Tanya L Hoskin; Courtney N Day; Elizabeth B Habermann; Judy C Boughey Journal: Ann Surg Oncol Date: 2019-07-22 Impact factor: 5.344
Authors: Richard J Bleicher; Karen Ruth; Elin R Sigurdson; J Robert Beck; Eric Ross; Yu-Ning Wong; Sameer A Patel; Marcia Boraas; Eric I Chang; Neal S Topham; Brian L Egleston Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Alina M Mateo; Anna M Mazor; Elias Obeid; John M Daly; Elin R Sigurdson; Elizabeth A Handorf; Lyudmila DeMora; Allison A Aggon; Richard J Bleicher Journal: Ann Surg Oncol Date: 2019-11-11 Impact factor: 5.344
Authors: Alok A Khorana; Katherine Tullio; Paul Elson; Nathan A Pennell; Stephen R Grobmyer; Matthew F Kalady; Daniel Raymond; Jame Abraham; Eric A Klein; R Matthew Walsh; Emily E Monteleone; Wei Wei; Brian Hobbs; Brian J Bolwell Journal: PLoS One Date: 2019-03-01 Impact factor: 3.240